A Pediatric Phase 1 Trial Of Vorinostat And Temozolomide In Relapsed Or Refractory Primary Brain Or Spinal Cord Tumors: A Children’s Oncology Group Phase 1 Consortium Study

PURPOSE: We conducted a pediatric phase I study to estimate the maximum tolerated dose (MTD), dose-limiting toxicities (DLT), and pharmacokinetic properties of vorinostat, a histone deacetylase (HDAC) inhibitor, when given in combination with temozolomide in children with refractory or recurrent CNS...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Päätekijät: Hummel, Trent R., Wagner, Lars, Ahern, Charlotte, Fouladi, Maryam, Reid, Joel M., McGovern, Renee M., Ames, Matthew M., Gilbertson, Richard J., Horton, Terzah, Ingle, Ashish M., Weigel, Brenda, Blaney, Susan M.
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: 2013
Aiheet:
Article
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC4139006/
https://ncbi.nlm.nih.gov/pubmed/23554030
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/pbc.24541
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia